Recommended Topic Related To:

Alora

"March 14, 2013 -- Hormone replacement therapy is the most effective treatment for symptoms like hot flashes, and the benefits are likely to outweigh the risks, major medical societies say.

The statement was published in the April issue "...

Alora

Alora

SIDE EFFECTS

See BOXED WARNINGS, WARNINGS and PRECAUTIONS.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates. Incidence of adverse events > 2% of each treatment group is given in Table 5.

Table 5: Incidence of Adverse Events > 2% for Alora (estradiol transdermal system) and Placebo Systems (data are expressed as N and (%) of treatment group)

Body System Preferred Term Placeboa
(N=87)
Alora (estradiol transdermal system) a
0.025 mg/day
(N=89)
Alora (estradiol transdermal system) a
0.05 mg/day
(N=90)
Alora (estradiol transdermal system) a
0.075 mg/day
(N=89)
Alora (estradiol transdermal system) b
0.1 mg/day
(N=174)
Body As A Whole
  Accidental Injury 4 (4.6) 6 (6.7) 8 (8.9) 4 (4.5) 9 (5.2)
  Allergic Reaction 2 (2.3) 4 (4.5) 4 (4.4) 2 (2.2) 1 (0.6)
  Asthenia 4 (4.6) 7 (7.9) 4 (4.4) 0 (0) 4 (2.3)
  Cyst 3 (3.4) 0 (0) 6 (6.7) 3 (3.4) 0 (0)
  Flu Syndrome 9 (10.3) 8 (9) 12 (13.3) 9 (10.1) 6 (3.4)
  Headache 11 (12.6) 10 (11.2) 8 (8.9) 5 (5.6) 37 (21.3)
  Infection 2 (2.3) 2 (2.2) 3 (3.3) 3 (3.4) 2 (1.1)
  Infection Fungal 1 (1.1) 3 (3.4) 9 (10) 4 (4.5) 0 (0)
  Pain 11 (12.6) 9 (10.1) 5 (5.6) 6 (6.7) 16 (9.2)
  Pain Abdominal 4 (4.6) 7 (7.9) 5 (5.6) 1 (1.1) 5 (2.9)
  Pain Back 5 (5.7) 5 (5.6) 3 (3.3) 7 (7.9) 11 (6.3)
  Pain Chest 4 (4.6) 4 (4.5) 2 (2.2) 1 (1.1) 2 (1.1)
Cardiovascular
  Hypertension 3 (3.4) 3 (3.4) 3 (3.3) 6 (6.7) 0 (0)
  Migraine 2 (2.3) 6 (6.7) 2 (2.2) 0 (0) 2 (1.1)
  Vasodilation 13 (14.9) 6 (6.7) 2 (2.2) 1 (1.1) 0 (0)
Digestive
  Constipation 4 (4.6) 3 (3.4) 6 (6.7) 1 (1.1) 3 (1.7)
  Diarrhea 2 (2.3) 1 (1.1) 3 (3.3) 2 (2.2) 5 (2.9)
  Dyspepsia 1 (1.1) 8 (9) 4 (4.4) 3 (3.4) 2 (1.1)
  Flatulence 5 (5.7) 1 (1.1) 2 (2.2) 3 (3.4) 8 (4.6)
  Gastroenteritis 2 (2.3) 3 (3.4) 4 (4.4) 3 (3.4) 0 (0)
  Nausea 3 (3.4) 6 (6.7) 5 (5.6) 3 (3.4) 7 (4)
Metabolic And Nutritional
  Edema Peripheral 4 (4.6) 3 (3.4) 4 (4.4) 3 (3.4) 3 (1.7)
  Weight Increased 4 (4.6) 3 (3.4) 2 (2.2) 4 (4.5) 1 (0.6)
Musculoskeletal
  Arthralgia 12 (13.8) 5 (5.6) 10 (11.1) 11 (12.4) 2 (1.1)
  Bone Fracture Spontaneous 7 (8) 1 (1.1) 3 (3.3) 0 (0) 0 (0)
  Joint Disorder 2 (2.3) 4 (4.5) 4 (4.4) 1 (1.1) 0 (0)
  Myalgia 4 (4.6) 3 (3.4) 2 (2.2) 5 (5.6) 3 (1.7)
Nervous
  Anxiety 3 (3.4) 0 (0) 9 (10) 2 (2.2) 3 (1.7)
  Depression 8 (9.2) 1 (1.1) 3 (3.3) 1 (1.1) 6 (3.4)
  Dizziness 0 (0) 1 (1.1) 7 (7.8) 4 (4.5) 1 (0.6)
  Hypesthesia 2 (2.3) 3 (3.4) 3 (3.3) 0 (0) 0 (0)
  Insomnia 7 (8) 4 (4.5) 2 (2.2) 1 (1.1) 8 (4.6)
Respiratory
  Asthma 1 (1.1) 3 (3.4) 3 (3.3) 1 (1.1) 2 (1.1)
  Bronchitis 6 (6.9) 7 (7.9) 4 (4.4) 4 (4.5) 6 (3.4)
  Cough Increased 2 (2.3) 1 (1.1) 4 (4.4) 1 (1.1) 6 (3.4)
  Infection Respiratory 23 (26.4) 22 (24.7) 22 (24.4) 19 (21.3) 28 (16.1)
  Pharyngitis 1 (1.1) 4 (4.5) 2 (2.2) 2 (2.2) 4 (2.3)
  Pneumonia 4 (4.6) 4 (4.5) 4 (4.4) 1 (1.1) 1 (0.6)
  Sinusitis 16 (18.4) 9 (10.1) 11 (12.2) 6 (6.7) 13 (7.5)
Skin
  Application Site Reaction 51 (58.6) 47 (52.8) 51 (56.7) 49 (55.1) 10 (5.7)
  Hirsutism 0 (0) 2 (2.2) 2 (2.2) 4 (4.5) 1 (0.6)
  Pruritus 4 (4.6) 2 (2.2) 1 (1.1) 6 (6.7) 9 (5.2)
  Rash 5 (5.7) 6 (6.7) 8 (8.9) 4 (4.5) 5 (2.9)
Special Senses
  Conjunctivitis 2 (2.3) 2 (2.2) 3 (3.3) 2 (2.2) 0 (0)
  Otitis Media 2 (2.3) 3 (3.4) 2 (2.2) 1 (1.1) 0 (0)
Urogenital
  Breast Enlargement 3 (3.4) 1 (1.1) 2 (2.2) 6 (6.7) 4 (2.3)
  Infection Urinary Tract 2 (2.3) 5 (5.6) 4 (4.4) 2 (2.2) 3 (1.7)
  Leukorrhea 1 (1.1) 3 (3.4) 2 (2.2) 4 (4.5) 3 (1.7)
  Neoplasm Breast 6 (6.9) 3 (3.4) 5 (5.6) 1 (1.1) 3 (1.7)
  Pain Breast 7 (8) 13 (14.6) 16 (17.8) 31 (34.8) 12 (6.9)
  Vaginitis 6 (6.9) 0 (0) 3 (3.3) 0 (0) 14 (8)
  Vaginal Bleedingc 4 (12.9) NA 6 (8.7) NA 29 (33.3)
a - Adverse events for the three lower Alora (estradiol transdermal system) doses and placebo were obtained from the two-year prevention of osteoporosis study
b - Adverse events for the highest Alora (estradiol transdermal system) doses were obtained from two 12-week studies of the treatment of menopausal symptoms
c - Data reported for women with partially or fully intact uteri in the menopausal symptom study only (N=31 for Placebo; N=69 for Alora (estradiol transdermal system) 0.05 mg/day and N=87 for Alora (estradiol transdermal system) 0.1 mg/day) NA – data not available

The following additional adverse reactions have been reported with estrogens and/or progestin therapy:

  1. Genitourinary system. Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow; breakthrough bleeding; spotting; increase in size of uterine leiomyomata; vaginitis, including vaginal candidiasis; change in amount of cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial hyperplasia; endometrial cancer.
  2. Breasts. Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic breast changes; breast cancer.
  3. Cardiovascular. Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis; myocardial infarction; stroke; increase in blood pressure.
  4. Gastrointestinal. Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased incidence of gall bladder disease; pancreatitis; enlargement of hepatic hemangiomas.
  5. Skin. Chloasma or melasma, which may persist when drug is discontinued; erythema multiform; erythema nodosum; hemorrhagic eruption; loss of scalp hair; hirsutism; pruritus; rash.
  6. Eyes.Retinal vascular thrombosis; intolerance to contact lenses.
  7. Central nervous system.Headache; migraine; dizziness; mental depression; chorea; nervousness; mood disturbances; irritability; exacerbation of epilepsy; dementia.
  8. Miscellaneous.Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of porphyria; edema; arthalgias; leg cramps; changes in libido; anaphylactoid/anaphylactic reactions including urticaria and angioedema; hypocalcemia; exacerbation of asthma; increased triglycerides.

Read the Alora (estradiol transdermal system) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Drug/Laboratory Test Interactions

  1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
  2. Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
  3. Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free hormone concentrations may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1- antitrypsin, ceruloplasmin).
  4. Increased plasma HDL and HDL2 subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels.
  5. Impaired glucose tolerance.
  6. Reduced response to the metyrapone test.

Last reviewed on RxList: 10/23/2008
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.

Health Resources
advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations